Mega Contracts Monitor ($100M+) — March 25, 2026

Three HHS contracts totaling $1.08B provide multi-year cash flow visibility for Elevance Health and Emergent BioSolutions through 2027-2029, with $514M already outlayed.

ElbitAmerica secures $105M firm fixed price for 2026-2030 persistent surveillance, marking future revenue ramp in security tech.

Neutral signals on $3.22B to nonprofits (Caltech, RTI, Mount Sinai) limit direct equity plays but affirm federal R&D priorities in space and vaccines.

Long tenures (2026-2030) across 83% of value expose to funding cuts, delays, or task order variability; $0 outlay on new DHS contract delays revenue.

Foreign ownership in Emergent Canada ($422M) and ElbitAmerica ($105M) risks policy scrutiny in health preparedness and border security.

Non-competed awards (50% of contracts) signal sole-source reliance but vulnerability if recompeted post-2028.

$201M+ in unexercised options across Emergent, Mount Sinai, and Elbit could boost topline if exercised.

HHS cluster ($1.19B) in Medicare IT, biodefense, and models support points to expanding health services demand.

Remaining $1.6B potential outlays (post-current spending) in cost-plus contracts offer steady nonprofit-partnered flows.

Four contracts totaling 28% of value focus on CMS IT, biodefense drugs, and R&D models through 2027, with 42% outlayed.

NASA's $3B JPL renewal and DHS $105M surveillance highlight non-competitive deep-pocket commitments in R&D and border tech.

{"entity"=>"Elevance Health (National Government Services)", "reason"=>"Largest for-profit HHS IT award ($505M, 51% outlayed) with steady CMS cash flows to 2027.", "trigger"=>"Outlays exceeding 70% or recompete signals"}

{"entity"=>"Emergent BioSolutions", "reason"=>"$422M biodefense obligation with $284M options upside to 2029 amid VIGIV demand.", "trigger"=>"Option exercises or ASPR budget hikes"}

{"entity"=>"ElbitAmerica / Elbit Systems", "reason"=>"Fresh $105M DHS surveillance start in 2026 with 2030 potential, no outlays yet.", "trigger"=>"Initial outlays or extension to 2030"}